Demegestone, a norprogesterone derivative, is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was marketed in France as Lutionex, but has since been discontinued. Demegestone has also been studied in combination with estrogens as an oral contraceptive and treatment for infertility. Demegestone did not exercise androgenic activity. Demegestone is the potent inhibitor of estrone sulfatase activity.

Cloricromen a drug that inhibits platelet aggregation in man and in experimental thrombosis. Experiments on rodents have revealed that cloricromene which reduced tumor necrosis factor production, could be useful in the treatment of periodontitis. In addition, it could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable. However, experiments with patients with cerebrovascular occlusive disease didn’t shown any effect of cloricromen on coagulative variables.

Cyromazine, an insect growth regulator, affects larval and pupal cuticles in dipterans and some other insects. The mode of action of this aminotriazine is not known yet, though it has been shown not to inhibit the synthesis of chitin and cuticular proteins. Cyromazine may, however, act on some step(s) of sclerotization of the cuticle. Cyromazine is not a cholinesterase inhibitor. As an insect growth regulator, cyrozine exerts its toxic action by affecting the nervous system of the immature stages (larvae) of certain insects.

YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.

Niflumic acid belongs to the group of nonsteroidal anti-inflammatory drugs (NSAIDs) and used in the treatment of rheumatoid arthritis, and joint and muscular pain. Its mechanism of action is believed to be based on selective inhibition of cycloxygenases-2 that results in antipyretic, analgesic, and anti-inflammatory effects. In addition to these effects on prostaglandin synthesis, it has been shown to act as a positive allosteric modulator on α1β2γ2 and as a negative modulator on α6β2 and α6β2γ2 (and α1β2) GABAA receptors. In addition, was reported, that niflumic acid blocked T-type calcium channels. It is available for clinical use in several European countries.

Oxametacin (1-p-chlorobenzoyl-2-methyl-5-methoxy-3-indolylacethydroxamic acid) is a non-steroidal anti-inflammatory compound that exerts analgesic, antipyretic and anti-inflammatory properties. This drug has been claimed to be effective in the treatment of acute attacks of gout. In the antiproliferative test, oxametacin exhibited leukemic cell lines selectivity against the solid tumor cell lines. Oxametacin also exhibited inhibitory activity toward histone deacetylases and thus could be used as a lead compound in the further development of histone deacetylase inhibitors for anticancer therapy.

Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Buclosamide (Jadit) is a topical antimycotic agent for the treatment of dermatomycoses. It was used as ointment or powder. Photo-allergic contact dermatitis from buclosamide was recorded.

Bucolome (Paramidine) is a barbiturate derivative. It is a non-steroidal anti-inflammatory drug, which is used in the treatment of chronic articular rheumatism. It has been used as a uricosuric and/or anti-inflammatory agent in Japan since 1967. Bucolome acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.

Bucetin [(3-hydroxy-p-butyrophenetidide) CAS: 1083-57-4) is a homologue to phenacetin and is used instead of phenacetin as an analgesic drug because of its lower toxicity than that of phenacetin, despite having equivalent analgesic activity when used at an appropriate dose. Dysplastic lesions of the proximal tubules were frequently seen in the males given bucetin in a dose-related fashion.